Clinical trials: Aggressive Behaviour
Molar-incisor Pattern Grade C Periodontitis ( Localized Aggressive Periodontitis), Generalized Grade C Periodontitis (Generalized Aggressive Periodontitis)
Apoptosis Markers in Aggressive Periodontitis
The aim of the present trial is to assess the gingival crevicular fluid level of caspase-3 and apoptosis inducing factor (AIF) in Generalized versus Molar-incisor grade C periodontitis.
- Trial name
- NCT04984031
- Testing
- ELISA assessment of apoptosis markers in gingival crevicular fluid
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Asem Mohammed Kamel Ali
Lymphoma
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.
- Trial name
- NCT07779018
- Testing
- CD22/CD19 CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liping Dou
Endocrine Tumor
A Research Registry on Aggressive PitNETs
To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours.
- Trial name
- RECAPitNETT (NCT05974696)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Alcohol Use Disorder, Intermittent Explosive Disorder
Neural Correlates During Alcohol Intoxication
Alcohol intoxication is responsible for a large proportion of violent crime/assault and personal injury in our society. While a number of variables have been associated with alcohol-related aggression, high trait aggression and…
- Trial name
- NCT06118580
- Testing
- Alcohol (Ethanol)
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative…
- Trial name
- Caprelsa104 (NCT01945762)
- Testing
- Vandetanib 300 mg
- Where
- 8 sites in Belgium, France and 6 more
- Volunteers
- 31 people
- Sponsor
- Genzyme, a Sanofi Company
Aggressive Behavior in Fragile X Syndome
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
The goal of this clinical trial is to learn if drug SRX246 works to treat irritability, agitation, aggression and self-injury (IAAS) behaviors in adult males with Fragile X Syndrome (FXS).
- Trial name
- NCT07328529
- Testing
- SRX246
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Azevan Pharmaceuticals
Adult T-cell Leukemia, Lymphoma
A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)
To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.
- Trial name
- NCT00145002
- Testing
- VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis, biweekly-CHOP with G-CSF and intrathecal prophylaxis
- Where
- Japan
- Volunteers
- 130 people
- Sponsor
- Japan Clinical Oncology Group
ST Elevation Myocardial Infarction
Aggressive hydraTion in Patients With ST -Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention to prevenT Contrast-Induced Nephropathy
To compare the efficacy of 2 different hydration strategies, hydration according to clinical guideline and adequate hydration, on contrast-induced nephropathy in patients with STEMI undergoing primary PCI to investigate the…
- Trial name
- ATTEMPT (NCT02067195)
- Testing
- Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride), 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Guangdong Provincial People's Hospital
Lymphoma
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
The aim of this study is to compare CHOP versus CEOP-induced cardiotoxicity in patients with aggressive B-cell lymphoma. The hypothesis is epirubicin is associated with less cardiotoxicity without compromising the efficacy.
- Trial name
- NCT00854568
- Testing
- CEOP regimen, CHOP regimen
- Where
- China
- Volunteers
- 398 people
- Sponsor
- Fudan University
Irritable Mood, Aggression
Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability
The purpose of this study is to determine if amantadine hydrochloride given 100 mg in the morning and at noon is safe and effective in the treatment of mood and behavior changes (i.e.
- Conditions
- Irritable Mood, Aggression, Traumatic Brain Injury
- Trial name
- NCT00627250
- Testing
- Amantadine
- Volunteers
- 76 people
- Sponsor
- Wake Forest University Health Sciences
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Prader-Willi Syndrome, Aggression
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS).
- Conditions
- Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes
- Trial name
- PWS-GXR (NCT05657860)
- Testing
- Guanfacine Extended Release
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Maimonides Medical Center
Cyberbullying Among Sohag University Students
Cyberbullying Among Sohag University Student
Cyberbullying can be defined as intentional aggression through electronic routes, such as text messages, e-mails, chat rooms, online games, and social websites.
- Trial name
- NCT05421026
- Volunteers
- 500 people
- Sponsor
- Sohag University
Autism, Asperger's Disorder
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
The aim of this study is to evaluate the efficacy, safety and tolerability of aripiprazole monotherapy in the treatment of children and adolescents suffering from Autism Spectrum Disorder (ASD) over a 12-week period.
- Conditions
- Autism, Asperger's Disorder, Pervasive Developmental Disorder
- Trial name
- NCT00308074
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cambridge Health Alliance
Aggressive Behavior
Can Psychodrama Improve Aggressive Behavior and Social Adaptation in Adolescent Boys?
This randomized controlled trial evaluated the effectiveness of a 10-session psychodrama intervention on reducing aggressive behavior and improving social adjustment among male adolescents with high aggression and low social…
- Trial name
- NCT07311174
- Testing
- Psychodrama, Control
- Where
- Iran
- Volunteers
- 22 people
- Sponsor
- Kerman University of Medical Sciences
Non-Hodgkin's Lymphoma
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments.
- Trial name
- NCT00323323
- Testing
- CHOP, Alemtuzumab, Plasma Samples
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
B-Cell Non-Hodgkin Lymphoma (B-NHL)
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to…
- Trial name
- OLYMPIA-4 (NCT06230224)
- Testing
- Odronextamab, Ifosfamide, Carboplatin
- Where
- 81 sites in Argentina, Australia and 12 more
- Volunteers
- 216 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Post-Traumatic Stress Disorder
Using Emotion Regulation to Decrease Aggression in Veterans With PTSD
Impulsive aggression (IA) is common among Veterans with posttraumatic stress disorder (PTSD), and PTSD is one of the most prevalent post deployment mental health conditions affecting Afghanistan and Iraq Veterans.
- Trial name
- (EMDA) (NCT02724787)
- Testing
- Manage Emotions to Reduce Aggression (MERA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Office of Research and Development
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00004112
- Testing
- rituximab, CHOP regimen, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- University of Nebraska
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden
This open-label, multi-cohorts, phase 1/2 study has the primary objective of comparing decitabine-primed tandem CART 19/20 solo, with decitabine-primed tandem CART 19/20 plus chidamide, decitabine-primed tandem CART 19/20 plus…
- Trial name
- NCT04553393
- Testing
- Chidamide, Decitabine, Chidamide and Decitabine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital